NSE · BETA

Beta Drugs Limited

Sector: Healthcare · ISIN: INE351Y01019

Historical price visualisation is temporarily undergoing corporate data-licensing maintenance. Full interactive price and chart data will return following our upcoming authorized NSE/BSE data-feed deployment. Derived metrics (valuation ratios, market-cap rank), company financials, shareholding, corporate actions, and mutual-fund holdings remain available.

Market cap rank

#1,153

of 5,072 stocks

▲ 111W

Peak #1,153 · 27 Sep 2026

Operating in Healthcare, Beta Drugs Limited carries a steep earnings multiple that prices in strong future growth, is growing revenue modestly, and earns a healthy return on equity. Ownership as of Jun 2026.

Market Cap

2,326.58 Cr

P/E Ratio

51.29

P/B Ratio

8.69

ROE

16.95%

ROCE

17.98%

Dividend Yield

—

52W High

—

52W Low

—

Quarterly financials

Metric	Q1 2026-27	Q4 2025-26	Q3 2025-26	Q2 2025-26
Revenue	125.55 Cr	93.96 Cr	87.27 Cr	203.59 Cr
Net Profit	16.49 Cr	9.05 Cr	8.52 Cr	23.92 Cr
EPS	14.78	8.93	8.40	47.38
Operating Profit	24.60 Cr	15.78 Cr	14.91 Cr	39.02 Cr

Figures in Cr (crore) unless noted. Source: official company financial disclosures.

Shareholding pattern

Promoter

59.10%

Public

40.90%

As of 30 Jun 2026. FII, DII, MF & Individuals are sub-categories of Public.

Mutual fund holdings

Mutual fund holdings data for this stock hasn't been ingested yet — check back soon.

Recent corporate actions

No corporate actions on record for this stock.

Need this data in your app?

Full price history, technical indicators, and every field above via one REST API call.

View API docs